AR075037A1 - Composiciones farmaceuticas de rendimiento de producto y cumplimiento del paciente superiores - Google Patents
Composiciones farmaceuticas de rendimiento de producto y cumplimiento del paciente superioresInfo
- Publication number
- AR075037A1 AR075037A1 ARP100100124A ARP100100124A AR075037A1 AR 075037 A1 AR075037 A1 AR 075037A1 AR P100100124 A ARP100100124 A AR P100100124A AR P100100124 A ARP100100124 A AR P100100124A AR 075037 A1 AR075037 A1 AR 075037A1
- Authority
- AR
- Argentina
- Prior art keywords
- composition
- composition according
- hydroxypropylcellulose
- pharmaceutical composition
- compliance
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente proporciona formulaciones de (2R,3R,4R,5R)-5-(4-amino-2-oxo-2H-pirimidin-1-iI)-4-fluoro-2-isobutiriloximetil-4-metil-tetrahidro-furan-3-il éster de ácido isobutírico e hidroxipropilcelulosa que proporcionan una elevada densidad aparente y un tamano de gránulo reducido más adecuados para una compresion y flujo mejorados, buena compresion, y perfiles de disolucion rápida. Reivindicacion 19: Composicion farmacéutica segun cualquiera de las reivindicaciones 1 a 18, en la que la composicion se detalla a continuacion: Ingrediente Intervalo % p/p Compuesto 1 50 - 95 Celulosa microcristalina 0 - 49 Croscarmelosa sodica 0 - 10 Hidroxipropilcelulosa 1 - 10 Talco 0 - 5 Estearato de magnesio 0 - 2 Composicion de recubrimiento con película Opadry« 0 - 5 Reivindicacion 20: Composicion farmacéutica segun la reivindicacion 19, en la que la composicion se detalla a continuacion: IngredienteComposicion % p/p Compuesto 1 77,0 Celulosa microcristalina 12,0 Croscarmelosa sodica 3,5 Hidroxipropilcelulosa 2,5 Talco 2,0 Estearato de magnesio 0,5 Composicion de recubrimiento con película Opadry« 2,5 Reivindicacion 21: Composicion farmacéutica segun cualquiera de las reivindicaciones 1 a 20, en la que la composicion se presenta en forma de tableta. Reivindicacion 22: Utilizacion de una composicion segun cualquiera de las reivindicaciones 1 a 21 para el tratamiento de una enfermedad mediada por el virus de la hepatitis C (VHC).
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14599909P | 2009-01-21 | 2009-01-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR075037A1 true AR075037A1 (es) | 2011-03-02 |
Family
ID=42026386
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP100100124A AR075037A1 (es) | 2009-01-21 | 2010-01-20 | Composiciones farmaceuticas de rendimiento de producto y cumplimiento del paciente superiores |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US8222230B2 (es) |
| EP (1) | EP2389164B1 (es) |
| JP (1) | JP5415561B2 (es) |
| KR (1) | KR101331723B1 (es) |
| CN (1) | CN102292075B (es) |
| AR (1) | AR075037A1 (es) |
| AU (1) | AU2010206224B2 (es) |
| BR (1) | BRPI1006924A2 (es) |
| CA (1) | CA2748895C (es) |
| CL (1) | CL2011001764A1 (es) |
| CO (1) | CO6440558A2 (es) |
| DK (1) | DK2389164T3 (es) |
| EC (1) | ECSP11011191A (es) |
| ES (1) | ES2513415T3 (es) |
| HK (1) | HK1164742A1 (es) |
| IL (1) | IL213804A0 (es) |
| MA (1) | MA32969B1 (es) |
| MX (1) | MX2011007771A (es) |
| NZ (1) | NZ593795A (es) |
| PE (1) | PE20120020A1 (es) |
| PL (1) | PL2389164T3 (es) |
| RU (1) | RU2489153C2 (es) |
| SG (1) | SG173001A1 (es) |
| SI (1) | SI2389164T1 (es) |
| TW (1) | TWI414295B (es) |
| UA (1) | UA100937C2 (es) |
| WO (1) | WO2010084041A2 (es) |
| ZA (1) | ZA201104882B (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012062691A1 (en) * | 2010-11-09 | 2012-05-18 | F. Hoffmann-La Roche Ag | Pharmaceutical compositions for treating hcv infections |
| CN105050708A (zh) | 2012-11-14 | 2015-11-11 | 格雷斯公司 | 含有生物活性材料与无序无机氧化物的组合物 |
| DE102013215831A1 (de) * | 2013-08-09 | 2015-02-12 | Beiersdorf Ag | Gelförmiges, alkoholisches Sonnenschutzmittel |
| WO2016121925A1 (ja) * | 2015-01-30 | 2016-08-04 | 協和発酵バイオ株式会社 | 機能性物質を高含有する錠剤及びその製造方法 |
| WO2017140253A1 (zh) * | 2016-02-19 | 2017-08-24 | 江苏恒瑞医药股份有限公司 | 一种含有咪唑啉类衍生物的药物组合物 |
| JP6323846B2 (ja) * | 2016-04-07 | 2018-05-16 | 塩野義製薬株式会社 | オピオイドを含有する乱用防止製剤 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUP0400726A3 (en) * | 2001-01-22 | 2007-05-29 | Merck & Co Inc | Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase |
| JP4408340B2 (ja) * | 2002-03-22 | 2010-02-03 | 武田薬品工業株式会社 | 速崩壊性固形製剤 |
| TWI332507B (en) * | 2002-11-19 | 2010-11-01 | Hoffmann La Roche | Antiviral nucleoside derivatives |
| KR20080027783A (ko) * | 2005-06-22 | 2008-03-28 | 다케다 야쿠힌 고교 가부시키가이샤 | 난용성 활성 성분을 함유하는 정제 |
| JP2008230967A (ja) * | 2005-06-23 | 2008-10-02 | Kowa Co | 医薬組成物 |
| NZ568909A (en) * | 2005-12-09 | 2011-10-28 | Hoffmann La Roche | Antiviral 4-fluoro-4-methyl nucleoside prodrugs |
| BRPI0619890A2 (pt) * | 2005-12-14 | 2011-10-25 | Hoffmann La Roche | composição farmacêutica e processo para preparação de uma suspensão sólida |
-
2010
- 2010-01-11 AU AU2010206224A patent/AU2010206224B2/en not_active Ceased
- 2010-01-11 UA UAA201110008A patent/UA100937C2/uk unknown
- 2010-01-11 PL PL10700233T patent/PL2389164T3/pl unknown
- 2010-01-11 SG SG2011051240A patent/SG173001A1/en unknown
- 2010-01-11 EP EP10700233.9A patent/EP2389164B1/en active Active
- 2010-01-11 SI SI201030785T patent/SI2389164T1/sl unknown
- 2010-01-11 PE PE2011001307A patent/PE20120020A1/es not_active Application Discontinuation
- 2010-01-11 JP JP2011546733A patent/JP5415561B2/ja not_active Expired - Fee Related
- 2010-01-11 WO PCT/EP2010/050182 patent/WO2010084041A2/en active Application Filing
- 2010-01-11 NZ NZ593795A patent/NZ593795A/xx not_active IP Right Cessation
- 2010-01-11 MA MA34019A patent/MA32969B1/fr unknown
- 2010-01-11 MX MX2011007771A patent/MX2011007771A/es active IP Right Grant
- 2010-01-11 KR KR1020117019277A patent/KR101331723B1/ko not_active IP Right Cessation
- 2010-01-11 BR BRPI1006924A patent/BRPI1006924A2/pt not_active IP Right Cessation
- 2010-01-11 CN CN2010800050195A patent/CN102292075B/zh not_active Expired - Fee Related
- 2010-01-11 CA CA2748895A patent/CA2748895C/en not_active Expired - Fee Related
- 2010-01-11 DK DK10700233.9T patent/DK2389164T3/da active
- 2010-01-11 RU RU2011134713/15A patent/RU2489153C2/ru not_active IP Right Cessation
- 2010-01-11 ES ES10700233.9T patent/ES2513415T3/es active Active
- 2010-01-18 US US12/689,004 patent/US8222230B2/en not_active Expired - Fee Related
- 2010-01-18 TW TW099101246A patent/TWI414295B/zh not_active IP Right Cessation
- 2010-01-20 AR ARP100100124A patent/AR075037A1/es unknown
-
2011
- 2011-06-28 IL IL213804A patent/IL213804A0/en unknown
- 2011-06-30 CO CO11082167A patent/CO6440558A2/es not_active Application Discontinuation
- 2011-07-01 ZA ZA2011/04882A patent/ZA201104882B/en unknown
- 2011-07-07 EC EC2011011191A patent/ECSP11011191A/es unknown
- 2011-07-21 CL CL2011001764A patent/CL2011001764A1/es unknown
-
2012
- 2012-06-12 HK HK12105721.1A patent/HK1164742A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR075037A1 (es) | Composiciones farmaceuticas de rendimiento de producto y cumplimiento del paciente superiores | |
| RU2744432C2 (ru) | Фармацевтическая композиция, включающая ингибитор янус-киназы или его фармацевтически приемлемую соль | |
| RU2016122609A (ru) | Составы соединений азаиндола | |
| HRP20201055T1 (hr) | Farmaceutske formulacije nitazoksanida s kontroliranim oslobađanjem | |
| RU2017133990A (ru) | Фармацевтические лекарственные формы ингибитора тирозинкиназы брутона | |
| NZ590184A (en) | Solid forms of (2s,3r,4r,5s,6r)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2h-pyran-3,4,5-triol and methods of their use | |
| EA201190012A1 (ru) | Твердые лекарственные формы бендамустина | |
| RU2012157256A (ru) | Фармацевтические композиции сокристаллов трамадола и коксибов | |
| HRP20151095T1 (hr) | Farmaceutski pripravci koji sadrže rifaksimin, postupci za njihovu proizvodnju i njihova primjena u lijeäśenju vaginalnih infekcija | |
| EA200800467A1 (ru) | Применение сложных эфиров гидроксибензойной кислоты и аналогов для получения лекарственного средства для предупреждения и лечения вирусной инфекции | |
| EA201291410A1 (ru) | Фармацевтические композиции, содержащие 4-амино-5-фтор-3-[6-(4-метилпиперазин-1-ил)-1h-бензимидазол-2-ил]-1h-хинолин-2-она лактат моногидрат | |
| RU2018127873A (ru) | Получение и составление композиции, содержащей ингибитор mek | |
| AR061790A1 (es) | Composicion farmaceutica solida para la administracion oral, formulaciones de comprimidos de liberacion inmediata de un antagonista del receptor de trombina, y su uso en la manufactura de un medicamento | |
| RU2014137096A (ru) | Перорально вводимая фармацевтическая композиция | |
| AR100977A1 (es) | Formulación compuesta para la administración oral que comprende ezetimiba y rosuvastatina, y un proceso para su preparación | |
| JP2024033011A (ja) | 医薬組成物 | |
| JP2024045760A (ja) | 医薬組成物 | |
| WO2007121545A8 (en) | S-nitrosothiols containing compositions for the treatment of fatty liver diseases, obesity and other diseases associated with the metabolic syndrome and the use of such compositions | |
| AR080895A1 (es) | Formulacion de comprimido de ezatiostat | |
| AR076220A1 (es) | Derivados de pirazol [4,5 - e] pirimidina | |
| ATE534382T1 (de) | Pharmazeutische zusammensetzungen von mit zuckeralkoholen zusammen mikronisiertem entacapon | |
| JP2008074790A (ja) | メサラジンを有効成分として含有する徐放性錠剤 | |
| RU2015112122A (ru) | Прероральная фармацевтическая композиция замедленного высвобождения, содержащая гидрохлорид гидроморфона | |
| CN111836620B (zh) | 一种海泽麦布和HMG-CoA还原酶抑制剂的药物组合物 | |
| RU2009101126A (ru) | Фармацевтическая композиция с антипсихотическим действием |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |